Will West

Will is an Investment Advisor at Morningside Venture Investments. He gained his PhD in 1991 in Immunology and Virology, sponsored by Unilever (UniPath), before holding a post-doctoral position at the National Institute of Biological Standards and Control (NIBSC). He went on to Procter & Gamble Healthcare, where he was responsible for clinical development in a number of therapeutic areas, including respiratory and GI. He led and delivered programmes throughout Europe, the Americas, South Africa and China.

In addition to F2G, Will is co-founder and CEO of CellCentric, a development-stage oncology company based on epigenetic research. He also oversees other Morningside biotech interests including chairing VaxEquity and Cyted. He is Chair of the John Innes Centre, the world-leading research institute focused on plant science and microbiology. In 2011 he was appointed by the Science Minister to the Council of the BBSRC, the UK’s leading funder of bioscience research. Will is on Board of the BioIndustry Association. He holds a Masters degree in Clinical Research as well as an MBA from London Business School.